Colon Cancer Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewColorectal cancer is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. In 2009, an estimated 106,100 new cases of colon and 40,870 cases of rectal cancer will occur. During the same year, it is estimated that 49,920 people will die from colon and rectal cancer.1 Despite these statistics, mortality from colon cancer has decreased slightly over the past 30 years, possibly due to earlier diagnosis through screening and better treatment modalities.This manuscript summarizes the NCCN Clinical Practice Guidelines in Oncology for managing colon cancer. The guidelines begin with clinical presentation to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance. When reviewing these guidelines, clinicians should be aware of...

If the inline PDF is not rendering correctly, you can download the PDF file here.


  • 1

    JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225229.

  • 2

    GreeneFPageDFlemingIFritzA. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.

  • 3

    HemminkiKEngC. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet2004;41:801807.

  • 4

    AhsanHNeugutAIGarbowskiGC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med1998;128:900905.

  • 5

    BonelliLMartinesHConioM. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer1988;41:513517.

  • 6

    ComptonCCGreeneFL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin2004;54:295308.

  • 7

    O’ConnellJBMaggardMAKoCY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst2004;96:14201425.

  • 8

    BurkeHB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst2004;96:14081409.

  • 9

    ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med2000;124:10161025.

  • 10

    ComptonCCFieldingLPBurgartLJ. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med2000;124:979994.

  • 11

    GreeneFLStewartAKNortonHJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg2002;236:416421.

  • 12

    SobinLHGreeneFL. TNM classification. Clarification of number of regional lymph nodes for pN0. Cancer2001;92:452.

  • 13

    SarliLBaderGIuscoD. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer2005;41:272279.

  • 14

    Le VoyerTSigurdsonEHamlinA. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol2003;21:29122919.

  • 15

    BilimoriaKPalisBStewartAK. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum2008;51:154161.

  • 16

    NewlandRCDentOFLyttleMN. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer1994;73:20762082.

  • 17

    ChapuisPHDentOFBokeyEL. Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer. Br J Surg2004;91:349354.

  • 18

    WongSLHongJHollenbeckBK. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA2007;298:21492154.

  • 19

    RedstonMComptonCCMiedemaBW. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B trial 80001. J Clin Oncol2006;24:878883.

  • 20

    SahaSVanABeutlerT. Sentinel lymph mapping techniques in colorectal cancer. Semin Oncol2004;31:374381.

  • 21

    WieseDASahaSBadinJ. Pathologic evaluation of sentinel lymph nodes in colorectal carcinoma. Arch Pathol Lab Med2000;124:17591763.

  • 22

    BertagnolliMMiedemaBRedstonM. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg2004;240:624628; discussion 628–630.

  • 23

    NouraSYamamotoHMiyakeY. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res2002;8:759767.

  • 24

    BaselgaJRosenN. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol2008;26:15821584.

  • 25

    AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:16261634.

  • 26

    Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:32303237.

  • 27

    De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508515.

  • 28

    PuntCJTolJRodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA 4011.

  • 29

    BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663771.

  • 30

    TejparSPeetersMHumbletY. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4001.

  • 31

    Van CutsemEHenning-KohneCHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 36014:14081417.

  • 32

    LièvreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374379.

  • 33

    KarapetisCSKhambata-FordSJonkerDJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:17571765.

  • 34

    LievreABachetJ-BBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol2008;26:374379.

  • 35

    ArtaleSSartore-BianchiAVeroneseSM. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:42174219.

  • 36

    Etienne-GrimaldiMCFormentoJLFrancoualM. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res2008;14:48304835.

  • 37

    CooperHSDeppischLMGourleyWK. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology1995;108:16571665.

  • 38

    MarkowitzAJWinawerSJ. Management of colorectal polyps. CA Cancer J Clin1997;47:93112.

  • 39

    NivatvongsSRojanasakulAReimanHM. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum1991;34:323328.

  • 40

    VolkEEGoldblumJRPetrasRE. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology1995;109:18011807.

  • 41

    UenoHMochizukiHHashiguchiY. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology2004;127:385394.

  • 42

    SeitzUBohnackerSSeewaldS. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum2004;47:17891796.

  • 43

    HaggittRCGlotzbachRESofferEEWrubleLD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology1985;89:328336.

  • 44

    CrawleyJPetrasRCareyW. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive cancer?Gastroenterology1986;91:419427.

  • 45

    WinawerSJFletcherRHMillerL. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology1997;112:594642.

  • 46

    BalthazarEJMegibowAJHulnickDNaidichDP. Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol1988;150:301306.

  • 47

    CohenAM. Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol1991;18:381387.

  • 48

    JosephNESigurdsonERHanlonAL. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol2003;10:213218.

  • 49

    BergerACSigurdsonERLeVoyerT. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol2005;23:87068712.

  • 50

    JohnsonPMPorterGARicciardiRBaxterNN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol2006;24:35703575.

  • 51

    LacyAMGarcia-ValdecasasJCDelgadoS. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet2002;359:22242229.

  • 52

    BuunenMVeldkampRHopWC. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol2009;10:4452.

  • 53

    JayneDGGuillouThorpeH. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol2007;25:30613068.

  • 54

    Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med2004;350:20502059.

  • 55

    FleshmanJSargentDJGreenE. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST study group trial. Ann Surg2007;246:655664.

  • 56

    KuhryESchwenkWGaupsetR. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev2008;CD003432.

  • 57

    BonjerHJHopWCNelsonH. Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg2007;142:298303.

  • 58

    JacksonTDKaplanGGArenaG. Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg2007;204:439446.

  • 59

    KuhryEBonjerHJHaglindE. Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc2005;19:687692.

  • 60

    KienlePWeitzJKochMBuchlerMW. Laparoscopic surgery for colorectal cancer. Colorectal Dis2006;8(Suppl 3):3336.

  • 61

    WagmanLJ. Laparoscopic and open surgery for colorectal cancer: reaching equipoise?J Clin Oncol2007;25:29962998.

  • 62

    WishnerJDBakerJWJrHoffmanGC. Laparoscopic-assisted colectomy. The learning curve. Surg Endosc1995;9:11791183.

  • 63

    NelsonHWeeksJCWieandHS. Proposed phase III trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer. J Natl Cancer Inst Monogr1995;19:5156.

  • 64

    OtaDNelsonHWeeksJ. Controversies regarding laparoscopic colectomy for malignant diseases. Curr Opin Gen Surg1994:208213.

  • 65

    SunWHallerDG. Adjuvant therapy of colon cancer. Semin Oncol2005;32:95102.

  • 66

    BaddiLBensonAIII. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist2005;10:325331.

  • 67

    BensonABIII. New approaches to the adjuvant therapy of colon cancer. Oncologist2006;11:973980.

  • 68

    AndreTBoniCMounedji-BoudiafL. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med2004;350:23432351.

  • 69

    de GramontABoniCNavarroM. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3501.

  • 70

    de GramontABoniCNavarroM. Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4007.

  • 71

    SargentDJWieandHSHallerDG. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2005;23:86648670.

  • 72

    SargentDJ. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient ACCENT dataset [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4008.

  • 73

    SargentDSobreroAGrotheyA. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2009;27:872877.

  • 74

    AndreTBoniCNavarroM. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol2009;27:31093116.

  • 75

    SaltzLNiedzwieckiDHollisD. Irinotecan fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol2007;25:34563461.

  • 76

    RothenbergMLMeropolNJPoplinEA. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol2001;19:38013807.

  • 77

    Van CutsemELabiancaRBodokyG. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol2009;27:31173125.

  • 78

    YchouMRaoulJLDouillardJY. A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol2009;20:674680.

  • 79

    WolmarkNWieandHKueblerJ. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3500.

  • 80

    KueblerJPWieandSO’ConnellMJ. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol2007;25:21982204.

  • 81

    TwelvesCWongANowackiMP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med2005;352:26962704.

  • 82

    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet1995;345:939944.

  • 83

    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol1999;17:13561363.

  • 84

    GillSLoprinziCLSargentDJ. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol2004;22:17971806.

  • 85

    SchragDRifas-ShimanSSaltzL. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol2002;20:39994005.

  • 86

    WolmarkNRocketteHMamounasE. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol1999;17:35533559.

  • 87

    HallerDGCatalanoPJMacdonaldJS. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol2005;23:86718678.

  • 88

    Quasar Collaborative GroupGrayRBarnwellJMcConkeyC. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet2007;370:20202029.

  • 89

    BensonABIIISchragDSomerfieldMR. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol2004;22:34083419.

  • 90

    LoveNBylundCMeropolNJ. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4200.

  • 91

    HongTSRitterMATomeWAHarariPM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer2005;92:18191824.

  • 92

    BensonABIII. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal appro0aches in early-stage disease. Clin Cancer Res2007;13:6913s6920s.

  • 93

    Van CutsemENordlingerBAdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:22122221.

  • 94

    YooPSLopez-SolerRILongoWEChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202207.

  • 95

    KemenyN. Management of liver metastases from colorectal cancer. Oncology (Williston Park)2006;20:116111761179; discussion 1179–1180 1185–1166.

  • 96

    MuratoreAZorziDBouzariH. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?Ann Surg Oncol2007;14:766770.

  • 97

    AlbertsSRHorvathWLSternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:92439249.

  • 98

    FongYCohenAMFortnerJG. Liver resection for colorectal metastases. J Clin Oncol1997;15:938946.

  • 99

    TsaiMSuYHoM. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol2007;14:786794.

  • 100

    PoultsidesGAServaisELSaltzLB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol2009;27:33793384.

  • 101

    FosterJH. Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis1984;4:170179.

  • 102

    StanglRAltendorf-HofmannACharnleyRMScheeleJ.. Factors influencing the natural history of colorectal liver metastases. Lancet1994;343:14051410.

  • 103

    VenookAP. The Kemeny article reviewed. Oncology2006;20:477484.

  • 104

    ChotiMASitzmannJVTiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759766.

  • 105

    PawlikTMScogginsCRZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715722.

  • 106

    CharnsangavejCClaryBFongY. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:12611268.

  • 107

    VautheyJNZorziDPawlikTM. Making unresectable hepatic colorectal metastases resectable--does it work?Semin Oncol2005;32(Suppl 9):S118122.

  • 108

    PozzoCBassoMCassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933939.

  • 109

    Altendorf-HofmannAScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am2003;12:165192.

  • 110

    PawlikTMSchulickRDChotiMA. Expanding criteria for resectability of colorectal liver metastases. Oncologist2008;13:5164.

  • 111

    FolprechtGGrotheyAAlbertsS. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol2005;16:13111319.

  • 112

    ReddySKPawlikTMZorziD. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol2007;14:34813491.

  • 113

    CoveyAMBrownKTJarnaginWR. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg2008;247:451455.

  • 114

    AdamRMillerRPitomboM. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am2007;16:525536.

  • 115

    AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737739.

  • 116

    AbdallaEKVautheyJNEllisLM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg2004;239:818825.

  • 117

    HurHKoYTMinBS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg2009;197:728736.

  • 118

    GleisnerALChotiMAAssumpcaoL. Colorectal liver metastases: recurrence and survival following hepatic resectin, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg2008;143:12041212.

  • 119

    ReuterNPWoodallCEScogginsCR. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?J Gastrointest Surg2009;13:486491.

  • 120

    BilchikAJPostonGAdamRChotiMA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol2008;26:53205321.

  • 121

    LeonardGDBrennerBKemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:20382048.

  • 122

    BenoistSBrouquetAPennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:39393945.

  • 123

    BilchikAJPostonGCurleySA. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol2005;23:90739078.

  • 124

    AdamRAvisarEAricheA. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol2001;8:347353.

  • 125

    RivoireMDe CianFMeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:22832292.

  • 126

    VautheyJNPawlikTMRiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:20652072.

  • 127

    PawlikTMOlinoKGleisnerAL. Preoperative chemotheapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg2007;11:860888.

  • 128

    PawlikTMPoonRTAbdallaEK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg2005;140:450457; discussion 457–458.

  • 129

    EliasDLiberaleGVernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900909.

  • 130

    FongYSaloJ. Surgical therapy of hepatic colorectal metastasis. Semin Oncol1999;26:514523.

  • 131

    AdamRDelvartVPascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644657.

  • 132

    DelaunoitTAlbertsSRSargentDJ. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol2005;16:425429.

  • 133

    NordlingerBSorbyeHGlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet2008;37:10071016.

  • 134

    TanBRZubalBHawkinsw. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases. Gastrointestinal Cancers Symposium2009; Abstract 497.

  • 135

    FolprechtGGruenbergerTHartmannJT. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 296.

  • 136

    SouglakosJAndroulakisNSyrigosK. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer2006;94:798805.

  • 137

    FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:16701676.

  • 138

    ScappaticciFAFehrenbacherLCartwrightT. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol2005;91:173180.

  • 139

    Package Insert. Bevacizumab (Avastin®). South San Francisco, CAGenentech, Inc.October2006.

  • 140

    GruenbergerBTamandlDSchuellerJ. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:18301835.

  • 141

    ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96106.

  • 142

    Rubbia-BrandtLAudardVSartorettiP. Severe hepatic sinusoidal obstructjion associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol2004;15:460466.

  • 143

    ZorziDKishiYMaruDM. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 295.

  • 144

    LeeWSYunSHChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699704.

  • 145

    HeadrickJRMillerDLNagorneyDM. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg2001;71:975979; discussion 979–980.

  • 146

    MitryEFieldsALABleibergH. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol2008;26:49064911.

  • 147

    KemenyNHuangYCohenAM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med1999;341:20392048.

  • 148

    KemenyNEGonenM. Hepatic arterial infusion after liver resection. N Engl J Med2005;352:734735.

  • 149

    MulcahyMFLewandowskiRJIbrahimSM. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer2009;115:18491858.

  • 150

    HongKMcBrideJDGeorgiadesCS. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol2009;20:360367.

  • 151

    KatzAWCarey-SampsonMMuhsAG. Hypofractionated stereotactic body radiation therapy (SBRT) for patients with limited hepatic metastases. Int J Radiat Oncol Biol Phys2007;67:793798.

  • 152

    DelbekeDMartinWH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med2004;34:209223.

  • 153

    BartlettDLBerlinJLauwersGY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:12841292.

  • 154

    YanTDBlackDSavadyRSugarbakerPH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol2006;24:40114019.

  • 155

    EsquivelJSticcaRSugarbakerP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol2007;14:128133.

  • 156

    PelosiEDeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol2007;33:16.

  • 157

    KellyHGoldbergRM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol2005;23:45534560.

  • 158

    GoldbergRM. Therapy for metastatic colorectal cancer. Oncologist2006;11:981987.

  • 159

    GoldbergRMRothenbergMLVan CutsemE. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist2007;12:3850.

  • 160

    GoldbergRMSargentDJMortonRF. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol2006;24:33473353.

  • 161

    DouillardJYCunninghamDRothAD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:10411047.

  • 162

    FuchsCSMooreMRHarkerG. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol2003;21:807814.

  • 163

    PetrelliNHerreraLRustumY. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol1987;5:15591565.

  • 164

    Van CutsemETwelvesCCassidyJ. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol2001;19:40974106.

  • 165

    Van CutsemEHoffPMHarperP. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer2004;90:11901197.

  • 166

    BurokerTRO’ConnellMJWieandHS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol1994;12:1420.

  • 167

    de GramontABossetJFMilanC. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol1997;15:808815.

  • 168

    Maindrault-GoebelFLouvetCAndreT. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer1999;35:13381342.

  • 169

    Van CutsemEPeetersMSienaS. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol2007;25:16581664.

  • 170

    CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337345.

  • 171

    van CutsemE. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist2006;11:10101017.

  • 172

    RaymondEFaivreSWoynarowskiJMChaneySG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol1998;25(Suppl 5):412.

  • 173

    O’DwyerPJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist2006;11:992998.

  • 174

    LentzFTranAReyE. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics2005;5:2133.

  • 175

    RothenbergMLBlankeCD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol1999;26:632639.

  • 176

    GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:2330.

  • 177

    TournigandCAndreTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229237.

  • 178

    DelaunoitTGoldbergRMSargentDJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer2004;101:21702176.

  • 179

    CheesemanSLJoelSPChesterJD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer2002;87:393399.

  • 180

    de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000;18:29382947.

  • 181

    ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol2005;23:48664875.

  • 182

    CassidyJClarkeSDiaz-RubioD. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 270.

  • 183

    CassidyJTaberneroJTwelvesC. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol2004;22:20842091.

  • 184

    PorschenRArkenauHTKubickaS. Phase III study of capecitabine plus oxaliplatin compared with fluororuracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol2007;25:42174223.

  • 185

    AndreTLouvetCMaindrault-GoebelF. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer1999;35:13431347.

  • 186

    JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:22742279.

  • 187

    WolmarkNRocketteHFisherB. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:18791887.

  • 188

    SaltzLBClarkeSDíaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:20132039.

  • 189

    SaltzLBClarkeSDiaz-RubioE. Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 238.

  • 190

    KabbinavarFFSchulzJMcCleodM. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol2005;23:36973705.

  • 191

    HurwitzHIFehrenbacherLHainsworthJD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol2005;23:35023508.

  • 192

    HochsterHSHartLLRamanathanRK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523–3529. Erratum in: J Clin Oncol2008;26:4697.

  • 193

    KabbinavarFFHambletonJMassRD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol2005;23:37063712.

  • 194

    HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:23352342.

  • 195

    FuchsCSMarshallJMitchellEP. Updated results of BICC-C study comparing first-line irinotecan /fluoropyrimidine combinations +/- celecoxib in mCRC: clinical data cut-off September 1, 2006 [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 276.

  • 196

    FuchsCJMarshallJBarruecoJ. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol2007;24:47794786.

  • 197

    SoberoAAcklandSCarrionR. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 3544.

  • 198

    GiantonioBCatalanoPMeropolN. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol2007;25:15391544.

  • 199

    CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:51505152.

  • 200

    Package insert. Capecitabine (Xeloda®)Nutley, NJRoche Laboratories Inc.June2005.

  • 201

    HallerDGCassidyJClarkeSJ. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol2008;26:21182123.

  • 202

    SchmollHJArnoldD. Update on capecitabine in colorectal cancer. Oncologist2006;11:10031009.

  • 203

    Package Insert. Irinotecan hydrochloride injection (Camptosar®)New York, NYPfizerJune2006.

  • 204

    InnocentiFUndeviaSDIyerL. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol2004;22:13821388.

  • 205

    LabCorp Capsule. UGT1A1 irinotecan toxicity. Managing medication dosing and predicting response to treatment of cancer with irinotecan (Camptosar CPT-11). 2006. Available at

  • 206

    O’DwyerPJCatalanoRB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol2006;24:45344538.

  • 207

    Package insert. Oxaliplatin (Eloxatin®)Bedford, OH. Ben Venue LaboratoriesNovember2004.

  • 208

    TournigandCCervantesAFigerA. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol2006;24:394400.

  • 209

    Maindrault-GoebelFLledoGGhibaudelB. Final results for OPTIMOX-2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: a GERCOR study [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4013.

  • 210

    GrotheyASargentDGoldbergRMSchmollHJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004;22:12091214.

  • 211

    CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352:14131418.

  • 212

    RougierPVan CutsemEBajettaE. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352:14071412.

  • 213

    PitotHRowlandKSargentDJ. N9841: a randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3506.

  • 214

    SaltzLBMeropolNJLoehrerPJSr. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol2004;22:12011208.

  • 215

    SaltzLRubinMHochsterH. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol2001;20:Abstract 7.

  • 216

    JonkerDJO’CallaghanCJKarapetisCS. Cetuximab for the treatment of colorectal cancer. J Clin Oncol2007;357:20402047.

  • 217

    SobreroAFMaurelJFehrenbacherL. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol2008;26:23112319.

  • 218

    HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672680.

  • 219

    Package Insert. Cetuximab (Erbitux®)Branchburg, NJImclone Systems, Inc.2004.

  • 220

    Package Insert. Panitumumab (Vectibix™)Thousand Oaks, CAAmgenSeptember2006.

  • 221

    HelblingDBornerM. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol2007;18:963964.

  • 222

    HeunJHolenK. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer2007;6:529531.

  • 223

    BerlinJvan CutsemEPeetersM. Predictive value of skin toxicity severity for response to panitumumab in pateints with metastatic colorectal cancer: a pooled analysis of five clinical trials [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4134.

  • 224

    HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672680.

  • 225

    TolJKoopmanMCatsA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med2009;360:563572.

  • 226

    HechtJMitchellEBarandaJ. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth receptor (EGFr) [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 3506.

  • 227

    GoldbergRMKohneGHSeymourMT. A pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials of 6,286 patients with metastatic colorectal cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4011.

  • 228

    HoffPMPazdurRLassereY. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol2004;22:20782083.

  • 229

    PietraNSarliLCostiR. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum1998;41:11271133.

  • 230

    SeccoGBFardelliRGianquintoD. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol2002;28:418423.

  • 231

    Rodriguez-MorantaFSaloJArcusaA. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol2006;24:386393.

  • 232

    FigueredoACharetteMLMarounJ. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol2004;22:33953407.

  • 233

    RenehanAGEggerMSaundersMPO’DwyerST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ2002;324:813.

  • 234

    JefferyMHickeyBHiderP. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev2007:CD002200.

  • 235

    DeschCEBensonABIIISomerfieldMR. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2005;23:85128519.

  • 236

    GuyotFFaivreJManfrediS. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol2005;16:756761.

  • 237

    Li DestriGDi CataldoAPuleoS. Colorectal cancer follow-up: useful or useless?Surg Oncol2006;15:112.

  • 238

    PfisterDGBensonABIIISomerfieldMR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med2004;350:23752382.

  • 239

    LockerGYHamiltonSHarrisJ. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol2006;24:53135327.

  • 240

    RexDKKahiCJLevinB. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin2006;56:160167.

  • 241

    GreenRJMetlayJPPropertK. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med2002;136:261269.

  • 242

    SprangersMAGTaalBGAaronsonNK. Quality of life in colorectal cancer: stoma vs. nonstoma patients. Dis Colon Rectum1995;38:361369.

  • 243

    DenlingerCSBarsevickAM. The Challenges of Colorectal Cancer Survivorship. J Natl Compr Cancer Netw2009; in press.

  • 244

    DignamJLPoliteBNYothersG. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst2006;98:16471654.

  • 245

    MeyerhardtJAHeseltineDNiedzwieckiD. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol2006;24:35353541.

  • 246

    MeyerhardtJANiedzwieckiDHollisD. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA2007;298:754764.

  • 247

    MartinEWJr.MintonJPCareyLC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg1985;202:310317.

Article Information


Google Scholar

Related Articles


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 115 115 38
PDF Downloads 32 32 22
EPUB Downloads 0 0 0